- Qfitlia (fitusiran) approved for routine prophylaxis in hemophilia A or B patients aged 12+ years.
- Subcutaneously administered, reduces bleeding rates by 73% in patients with inhibitors and 71% in those without inhibitors.
- Carries a boxed warning for thrombotic events and gallbladder disease, including hepatotoxicity.
- Common side effects: viral infections, nasopharyngitis, and bacterial infections.
- Orphan Drug and Fast Track designations from the FDA.
Daily News
Stay up to date with the latest clinical headlines and other information tailored to your specialty.
